Skip to content

Study · Animal study (in vivo) · dog · 2013

4 results

Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs.

Boucheix OB, Milano SP, Henriksson M, Reinheimer TM

Shock (Augusta, Ga.)1 Jun 2013Cited by 12 (Europe PMC)

PMID23429645 (opens in a new tab)DOI10.1097/shk.0b013e31828aac4b (opens in a new tab)PepBankPUB-23429645
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In healthy dogs, selepressin and arginine vasopressin induced similar mean blood pressure increases, reported together as +13% to 18%.

    In plain wordsIn dogs, selepressin and arginine vasopressin produced similar increases in mean blood pressure.

    Peptide
    Selepressin
    Outcome
    IncreaseMean blood pressure
    Study

    dogsn = 8

    Anesthetized healthy dogs after thoracotomy
    Comparator
    Arginine vasopressin
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1-300 ng · kg(-1) · min(-1) · infusionAs given in this study (dogs).

    Source sentences

    Summary
    Selepressin and AVP induced a similar increase in mean blood pressure (+13% to 18%)
    3 context sentences
    Summary · context
    Its effect on coronary and aortic blood flow, hemodynamics, and electrocardiogram as an indication of drug safety in healthy dogs was compared with arginine vasopressin (AVP).
    Summary · context
    Eight dogs were fasted, anesthetized, intubated, and ventilated.
    Summary · context
    Selepressin or AVP was administered by dose-escalating infusions (1-300, 0.3-100 ng · kg(-1) · min(-1), respectively).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In healthy dogs, selepressin and arginine vasopressin produced similar decreases in aortic blood flow, reported together as -40% to 45%.

    In plain wordsIn dogs, selepressin and arginine vasopressin produced similar decreases in aortic blood flow.

    Peptide
    Selepressin
    Outcome
    DecreaseAortic blood flow
    Study

    dogsn = 8

    Anesthetized healthy dogs after thoracotomy
    Comparator
    Arginine vasopressin
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1-300 ng · kg(-1) · min(-1) · infusionAs given in this study (dogs).

    Source sentences

    Summary
    Selepressin and AVP induced a similar increase in mean blood pressure (+13% to 18%), a moderate decrease in aortic blood flow (-40% to 45%), and a slight decrease in coronary blood flow (-16% to 22%).
    3 context sentences
    Summary · context
    Its effect on coronary and aortic blood flow, hemodynamics, and electrocardiogram as an indication of drug safety in healthy dogs was compared with arginine vasopressin (AVP).
    Summary · context
    Eight dogs were fasted, anesthetized, intubated, and ventilated.
    Summary · context
    Selepressin or AVP was administered by dose-escalating infusions (1-300, 0.3-100 ng · kg(-1) · min(-1), respectively).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In healthy dogs, selepressin and arginine vasopressin produced similar decreases in coronary blood flow, reported together as -16% to 22%.

    In plain wordsIn dogs, selepressin and arginine vasopressin produced similar decreases in coronary blood flow.

    Peptide
    Selepressin
    Outcome
    DecreaseCoronary blood flow
    Study

    dogsn = 8

    Anesthetized healthy dogs after thoracotomy
    Comparator
    Arginine vasopressin
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1-300 ng · kg(-1) · min(-1) · infusionAs given in this study (dogs).

    Source sentences

    Summary
    Selepressin and AVP induced a similar increase in mean blood pressure (+13% to 18%), a moderate decrease in aortic blood flow (-40% to 45%), and a slight decrease in coronary blood flow (-16% to 22%).
    3 context sentences
    Summary · context
    Its effect on coronary and aortic blood flow, hemodynamics, and electrocardiogram as an indication of drug safety in healthy dogs was compared with arginine vasopressin (AVP).
    Summary · context
    Eight dogs were fasted, anesthetized, intubated, and ventilated.
    Summary · context
    Selepressin or AVP was administered by dose-escalating infusions (1-300, 0.3-100 ng · kg(-1) · min(-1), respectively).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In healthy dogs, selepressin and arginine vasopressin produced more pronounced peripheral vasoconstriction than increased coronary resistance.

    In plain wordsIn dogs, selepressin and arginine vasopressin narrowed peripheral vessels more than they increased coronary resistance.

    Peptide
    Selepressin
    Outcome
    IncreasePeripheral vasoconstriction relative to coronary resistance
    Study

    dogsn = 8

    Anesthetized healthy dogs after thoracotomy
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    1-300 ng · kg(-1) · min(-1) · infusionAs given in this study (dogs).

    Source sentences

    Summary
    These vasopressors displayed similar hemodynamic characteristics, with peripheral vasoconstriction and decreased aortic blood flow being more pronounced than the increase in coronary resistance and decrease in coronary blood flow.
    3 context sentences
    Summary · context
    Its effect on coronary and aortic blood flow, hemodynamics, and electrocardiogram as an indication of drug safety in healthy dogs was compared with arginine vasopressin (AVP).
    Summary · context
    Eight dogs were fasted, anesthetized, intubated, and ventilated.
    Summary · context
    Selepressin or AVP was administered by dose-escalating infusions (1-300, 0.3-100 ng · kg(-1) · min(-1), respectively).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.